Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.

Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Author information

1
Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom. Electronic address: curlymorris_cliff@yahoo.com.
2
Centro di Biostatistica e Bioinformatica, Università di Roma Tor Vergata, Rome, Italy.
3
Department of Medicine, Karolinska Institutet & Karolinska University Hospital, Huddinge, Stockholm, Sweden.
4
European Group for Blood and Marrow Transplantation Data Office, Leiden University Medical Centre, Leiden, The Netherlands.
5
Haematology Department, Belfast City Hospital, Belfast, United Kingdom.
6
Department of Haematology, Saint Antoine Hospital, Paris, France.
7
Leukaemia Myeloma Units, Royal Marsden Hospital, London Surrey, United Kingdom.
8
Department of Hematology, University Medical Center St, Radboud, Nijmegen, The Netherlands.
9
Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
10
Service d'Hematologie, Centre Pierre et marie Curie, Alger, Algeria.
11
Sezione di Ematologia, University of Perugia, Perugia, Italy.
12
Department of Hematology, University Medical Center, Utrecht, The Netherlands.
13
Department of Hematology, Hospital Clinic, Barcelona, Spain.
14
Institute of Hematology, Bologna University S. Orsola, Bologna, Italy.
15
Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
16
Tumor Immunology, University Medical Center St, Radboud, Nijmegen, The Netherlands.

Abstract

We have recently reported on the outcome of autologous transplantation in the rare myelomas (IgD, IgE, IgM, and nonsecretory [NS]) but there is no real information on the outcome of these conditions after allogeneic transplantation. We used the European Group for Blood and Marrow Transplantation myeloma database to compare the outcomes after allogeneic transplantation of 1354 common myelomas (IgG, IgA, and light chain myeloma) with the outcome in 26 IgD myelomas and 52 NS myelomas. There was little difference between common and the IgD and NS myeloma patients with respect to prognostic factors although the IgD group had a higher beta 2 microglobulin at diagnosis, shorter time to transplantation, and more T cell depletion. IgD and NS patients had a significantly greater achievement of complete remission at conditioning but this did not translate into equivalent progression-free survival and overall survival for the IgD patients although the NS outcome was very similar to that of common myeloma. The PFS and OS of IgD, common, and NS myelomas appear similar after allogeneic transplantation, despite a tendency for higher early relapse rate in IgD myeloma. Allogeneic transplantation may, therefore, be an option to investigate in prospective observational studies.

KEYWORDS:

Allogeneic transplantation; IgD; Myeloma; Nonsecretory myeloma

PMID:
25708221
DOI:
10.1016/j.bbmt.2015.02.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center